• SEPTEMBER 25, 2013

Ranbaxy woes don't seem to end

Here is today's recommended reading list from Equitymaster...

Ranbaxy woes don't seem to end
Since the first legal case slammed in 2007 by a former employee for forging drug clinical trial studies, the ghost of inadequate practices keep haunting Ranbaxy. Recently, United States Food & Drug Administration imposed a ban on the firm's new plant at Mohali in Punjab, making it the third ban on a Ranbaxy plant in five years. In its rush to capitalize on the growing overseas market of cheap generic drugs, the company seems to have gone lax on quality issues. Read on to know more... (The Economist Newspaper Limited)

Functioning of economy, demystified
Since the eruption of the global financial crisis in 2008, the functioning of economies across the world have been a heated topic of debate. In this video Mr Ray Dalio explains the working of the economy in layman's terms. Watch it to understand how the economy can impact the well being of its inhabitants. (Value Investing World)

Corporate India continues to reel under rate hike
The recent hike in the repo rate further compounded funding problems of corporate India. With companies already struggling with the economic slowdown and falling profits, the rising cost of funds is adding on to their burden. Companies are deferring bond issues or raising funds at higher market rates. Read on to find out how high rates are impacting the financial health of companies... (Thomson Reuters)

Simplifying energy needs of industry
In a bid to expedite investments in the energy sector and bring in more transparency, the government has approved auction-based bidding for coal mining licenses by private companies. While bidding will be competitive for deregulated sectors such cement and steel, discounts will be offered to the regulated power sector on the basis of tariff-based bidding. Read on to know more... (Thomson Reuters)

Are dividends value accretive?
The surplus cash generated by any business can either be ploughed back into the business or returned back to shareholders. In the latter case, the cash can be returned in the form of dividends or share buyback. Which among the two options will maximize shareholder's wealth? Read on to find out... (Inside Investing)

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407